StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Chandan Taparia, Motilal Oswal

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byChandan Taparia, Motilal OswalHorizon: NA (inferred Swing (≤2wk))21 Aug 2026via LiveMint Markets

Entry₹2,334.6Inferred
Target₹2,470
Total upside +5.80% (call closed)
Stop loss₹2,260-3.20% risk
Exit₹2,47027 Aug 2026, 9:20 am
Target hit+5.80%0.00%upside left
Follow Chandan Taparia for new calls(31% target hit, 250 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 147 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 27 Aug 2026
3 supporting1 neutral1 opposing
Supports the BUY call (3)

3 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·25 Aug · 2d ago

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 6d ago

(opens in new tab)

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Chandan Taparia, Motilal Oswal

Every call and its outcome